Author:
Fang Douglas D.,Zhang Cathy C.,Gu Yin,Jani Jitesh P.,Cao Joan,Tsaparikos Konstantinos,Yuan Jing,Thiel Melissa,Jackson-Fisher Amy,Zong Qing,Lappin Patrick B.,Hayashi Tomoko,Schwab Richard B.,Wong Anthony,John-Baptiste Annette,Bagrodia Shubha,Los Geritt,Bender Steve,Christensen James,VanArsdale Todd
Publisher
Public Library of Science (PLoS)
Reference47 articles.
1. Cancer statistics, 2012;R Siegel;CA Cancer J Clin,2012
2. Targeting the phosphoinositide 3-kinase pathway in cancer;P Liu;Nat Rev Drug Discov,2009
3. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.Cancer Res;NT Ihle,2009
4. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.Mol Cancer Ther;F Janku,2011
5. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials;F Janku;Cancer Res,2012
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献